News

Swiss Topadur Pharma AG collaborates with South Korean Juvic Inc. and the research group led by Prof. Hyungil Jung at Yonsei University in Seoul

News 04.01.2024 Zurich-Schlieren, Switzerland, 20 December 2023 Swiss Topadur Pharma AG, in collaboration with South Korean Juvic Inc. and the research group led by Prof. Hyungil Jung at Yonsei University in Seoul, has launched a project to improve disease management in systemic sclerosis. The project particularly aims to enhance treatment for patients who...

read more

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

News 04.01.2024 Schlieren (Zurich), Switzerland, January 4, 2024 – Kuros Biosciences, a leader in next generation bone graft technologies, announced today three advancements related to its MagnetOs portfolio of products: specifically positive results from the MAXA level 1 clinical trial comparing standalone MagnetOs to autograft in a  real world patient population in...

read more

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

News 20.12.2023 SCHLIEREN, Switzerland & ROCKVILLE, Md.--(BUSINESS WIRE)--LimmaTech Biologics and AbVacc announced today a license agreement that grants LimmaTech the exclusive rights to further develop AbVacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by the bacterial pathogen, Staphylococcus aureus (S. aureus). LimmaTech also receives an exclusive option, executable post Phase 1...

read more